Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.
(2013) Annals of Oncology — Vol. 24, n° 9, p. 2261-2266 (2013)
Files
Schmitz-2013-Tumourresponseandsafety.pdf
Restricted Access - Adobe PDF
- 477.31 KB
Details
- Authors
- Abstract
- Short-course pre-operative administration of cetuximab is safe and shows a high rate of (18)FDG-PET response. (18)FDG-PET response was correlated with residual tumour cellularity suggesting that (18)FDG-PET deserves further investigation as a potential early marker of cetuximab activity in SCCHN.
- Affiliations
Citations
Schmitz, S., Hamoir, M., Reychler, H., Magremanne, M., Weynand, B., Lhommel, R., Hanin, F.-X., Duprez, T., Michoux, N., Rommel, D., Lonneux, M., Cappoen, N., Gillain, A., & Machiels, J.-P. (2013). Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Annals of Oncology, 24(9), 2261-2266. https://doi.org/10.1093/annonc/mdt180 (Original work published 2013)